Payment overview · 2025
General Payments
$398.54
23 reported records · 8 companies
Healthcare provider profile · identity verified
Kerry D Mccarroll, MD
Allopathic & Osteopathic Physicians|Family Medicine · ALVIN, TX · NPI 1568448181
Verified facts
What the public records show
CMS Open Payments records show Kerry D Mccarroll, MD received $398.54 in general payments during 2025 across 23 reported records.
Exact Sciences Corporation accounted for 40.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $162.70 | 40.8% | 10 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $44.42 | 11.2% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $44.18 | 11.1% | 3 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $40.80 | 10.2% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $39.16 | 9.8% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $32.75 | 8.2% | 2 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $19.81 | 5.0% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.72 | 3.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $398.54 | 23 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $162.70 | 10 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $40.80 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $39.16 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $32.75 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $29.79 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $29.79 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $29.79 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $19.81 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $14.72 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAMAX Normalized: vyndamax |
Drug | PFIZER INC. | $14.63 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 56 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
56 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
80 | 20 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 884 | 278 |
| Lisinopril | Lisinopril | 488 | 166 |
| Levothyroxine Sodium | Levothyroxine Sodium | 480 | 149 |
| Pantoprazole Sodium | Pantoprazole Sodium | 408 | 134 |
| Metformin Hcl | Metformin Hcl | 406 | 128 |
| Amlodipine Besylate | Amlodipine Besylate | 353 | 116 |
| Losartan Potassium | Losartan Potassium | 307 | 103 |
| Tamsulosin Hcl | Tamsulosin Hcl | 287 | 101 |
| Simvastatin | Simvastatin | 263 | 83 |
| Omeprazole | Omeprazole | 248 | 75 |
| Metoprolol Succinate | Metoprolol Succinate | 232 | 82 |
| Hydrochlorothiazide | Hydrochlorothiazide | 223 | 80 |
| Gabapentin | Gabapentin | 214 | 80 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 210 | 66 |
| Meloxicam | Meloxicam | 187 | 72 |
| Clopidogrel | Clopidogrel Bisulfate | 183 | 61 |
| Escitalopram Oxalate | Escitalopram Oxalate | 178 | 58 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 177 | 55 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 157 | 51 |
| Montelukast Sodium | Montelukast Sodium | 149 | 52 |
| Glipizide | Glipizide | 143 | 42 |
| Trazodone Hcl | Trazodone Hcl | 135 | 44 |
| Metoprolol Tartrate | Metoprolol Tartrate | 134 | 43 |
| Glimepiride | Glimepiride | 133 | 45 |
| Furosemide | Furosemide | 123 | 44 |
| Carvedilol | Carvedilol | 119 | 41 |
| Allopurinol | Allopurinol | 104 | 36 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 96 | 32 |
| Metformin Hcl Er | Metformin Hcl | 95 | 34 |
| Atenolol | Atenolol | 94 | 28 |
| Sertraline Hcl | Sertraline Hcl | 93 | 28 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 88 | 30 |
| Naproxen | Naproxen | 86 | 42 |
| Pravastatin Sodium | Pravastatin Sodium | 85 | 26 |
| Clonazepam | Clonazepam | 83 | 12 |
| Eliquis | Apixaban | 80 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 79 | 38 |
| Potassium Chloride | Potassium Chloride | 68 | 21 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 64 | 58 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 62 | 19 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 61 | 21 |
| Pioglitazone Hcl | Pioglitazone Hcl | 61 | 22 |
| Citalopram Hbr | Citalopram Hydrobromide | 58 | 21 |
| Clonidine Hcl | Clonidine Hcl | 57 | 18 |
| Jardiance | Empagliflozin | 56 | 19 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 54 | 33 |
| Valsartan | Valsartan | 54 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 50 | 18 |
| Fenofibrate | Fenofibrate Nanocrystallized | 50 | 13 |
| Finasteride | Finasteride | 50 | 15 |
| Tizanidine Hcl | Tizanidine Hcl | 49 | 26 |
| Ibuprofen | Ibuprofen | 47 | 19 |
| Ozempic | Semaglutide | 45 | 13 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 44 | 18 |
| Spironolactone | Spironolactone | 42 | 13 |
| Zolpidem Tartrate | Zolpidem Tartrate | 41 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 38 | 11 |
| Baclofen | Baclofen | 37 | 22 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 37 | 13 |
| Synthroid | Levothyroxine Sodium | 37 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 36 | 13 |
| Buspirone Hcl | Buspirone Hcl | 35 | 15 |
| Fenofibrate | Fenofibrate | 35 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 35 | 19 |
| Rybelsus | Semaglutide | 35 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 34 | 14 |
| Warfarin Sodium | Warfarin Sodium | 34 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 33 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 32 | 31 |
| Trulicity | Dulaglutide | 32 | suppressed |
| Xarelto | Rivaroxaban | 32 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 31 | 11 |
| Methylprednisolone | Methylprednisolone | 31 | 28 |
| Sumatriptan Succinate | Sumatriptan Succinate | 31 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 30 | suppressed |
| Glipizide Er | Glipizide | 30 | suppressed |
| Lovastatin | Lovastatin | 30 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 30 | 11 |
| Bupropion Hcl Sr | Bupropion Hcl | 29 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 29 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 28 | suppressed |
| Tradjenta | Linagliptin | 28 | suppressed |
| Bupropion Xl | Bupropion Hcl | 27 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 27 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 27 | 12 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 27 | suppressed |
| Mirtazapine | Mirtazapine | 26 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 26 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 25 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 25 | 15 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 24 | suppressed |
| Carbamazepine | Carbamazepine | 24 | suppressed |
| Fluconazole | Fluconazole | 24 | 15 |
| Diclofenac Potassium | Diclofenac Potassium | 23 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 23 | suppressed |
| Lorazepam | Lorazepam | 23 | suppressed |
| Myrbetriq | Mirabegron | 23 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 23 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 23 | 11 |
| Ezetimibe | Ezetimibe | 22 | suppressed |
| Nifedipine Er | Nifedipine | 22 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 22 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 21 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 21 | 12 |
| Famotidine | Famotidine | 21 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 21 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 21 | suppressed |
| Levetiracetam | Levetiracetam | 20 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 19 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Celecoxib | Celecoxib | 18 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 18 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 18 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 18 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 18 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 18 | suppressed |
| Gemfibrozil | Gemfibrozil | 17 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 17 | 16 |
| Verapamil Er | Verapamil Hcl | 17 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 16 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 16 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 16 | suppressed |
| Ramipril | Ramipril | 16 | suppressed |
| Alprazolam | Alprazolam | 15 | suppressed |
| Chlorthalidone | Chlorthalidone | 15 | suppressed |
| Lansoprazole | Lansoprazole | 15 | suppressed |
| Methocarbamol | Methocarbamol | 15 | 11 |
| Novolog Flexpen | Insulin Aspart | 15 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 15 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 15 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 14 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 14 | suppressed |
| Prednisone | Prednisone | 14 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 13 | suppressed |
| Cephalexin | Cephalexin | 13 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 13 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 13 | 11 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Telmisartan | Telmisartan | 13 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 12 | 12 |
| Dutasteride | Dutasteride | 12 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 11 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 11 | suppressed |
| Lactulose | Lactulose | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $398.54 · 23 records | Exact Sciences Corporation | ABRYSVO, COMIRNATY, Cologuard Collection Kit, JARDIANCE, KRYSTEXXA, Kerendia, Leqembi, NEXLETOL, PREVNAR 20, VYNDAMAX | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error